The Royal College of Physicians Simms Lecture, 6 December 2011: Clinical research networks and the benefits of intensive healthcare systems

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 12, Issue 5, 2012, Pages 446-452

  Selby, Peter ^a   Kaplan, Richard ^b,c   Cameron, David ^d,e   Cooper, Matthew ^f   Seymour, Matthew ^a,f  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e NHS LOTHIAN   (United Kingdom)

^f NIHR Cancer Research Network   (United Kingdom)

Author keywords

Clinical research networks; Research intensive healthcare systems

Indexed keywords

CANCER SCREENING; CLINICAL PRACTICE; CLINICAL RESEARCH; CONFERENCE PAPER; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; INDIA; NATIONAL HEALTH SERVICE; UNITED KINGDOM;

EID: 84867917510     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.12-5-446     Document Type: Conference Paper

References (41)

1. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004;363:263-70. (Pubitemid 38142408)
2. Vist GE, Bryant D, Somerville L et al. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2008:MR000009.
3. Selby P, Autier P. The impact of the process of clinical research on health service outcomes. Ann Oncol 2011;22(Suppl 7):vii5-9.
4. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989;299:1069-72. (Pubitemid 19262532)
5. du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 2005;15:183-91. (Pubitemid 40396951)
6. Majumdar SR, Roe MT, Peterson ED et al. Better outcomes for patients treated at hospitals that participate in clinical trials. Arch Intern Med 2008;168:657-62. (Pubitemid 351468401)
7. Clarke M, Loudon K. Effects on patients of their healthcare practitioner's or institution's participation in clinical trials: a systematic review. Trials 2011;12:16.
8. Krzyzanowska MK, Kaplan R, Sullivan R. How may clinical research improve healthcare outcomes? Ann Oncol 2011;22(Suppl 7):vii10-5.
9. Sankaranarayanan R, Sauvaget C, Ramadas K et al. Clinical trials of cancer screening in the developing world and their impact on cancer healthcare. Ann Oncol 2011;22(Suppl 7):vii20-8.
10. Cameron D, Stead M, Lester N et al. Research-intensive cancer care in the NHS in the UK. Ann Oncol 2011;22(Suppl 7):vii29-35.
11. Darbyshire J, Sitzia J, Cameron D et al. Extending the clinical research network approach to all of healthcare. Ann Oncol. 2011: 22(Suppl 7):vii36-43.
12. Stead M, Cameron D, Lester N et al. Strengthening clinical cancer research in the United Kingdom. Br J Cancer 2011;104:1529-34.
13. NIHR. NIHR Clinical Research Network Activity Report. Quarter 3, 2011/12. London: NIHR, 2012.
14. Stewart D, Wilson R, Selby P, Darbyshire J. Patient and public involvement. Ann Oncol 2011;22(Suppl 7):vii54-6.
15. Coleman RE, Marshall H, Cameron D et al. Breast-Cancer Adjuvant Therapy with Zoledronic Acid. N Engl J Med 2011;365:1396-1405.
16. Burger RA, Brady MF, Bookman MA et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med 2011;365:2473-2483.
17. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 2011;377:2103-2114.
18. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet Oncology 2011;12:642-653.
19. Bolla M, Van Tienhoven G, Padraig Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.The Lancet Oncology 2010;11:1066-1073.
20. Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer.The Lancet Oncology 2010;11:85-91.
21. Rustin GJS, van der Burg MEL, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet 2010;376:1155-1163.
22. Turnbull L, Brown S, Harvey I et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. The Lancet 2010;375:563-571.
23. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. JCO 2007:2212-2217.
24. Allum WH, Stenning SP, Bancewicz J et al. Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer. JCO 2009:5062-5067.
25. Parmar MKB, Griffiths GO, Spiegelhalter DJ et al. Monitoring of large randomised clinical trials: a new approach with Bayesian methods. The Lancet 2011;358:375-381.
26. Ellis P, Barrett-Lee P, Johnson L et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. The Lancet 2009;373:1681-1692.
27. Earl HM, Vallier A, Hiller L et al. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR), J Clin Oncol 2009;27:15s (suppl;abstr 522).
28. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. The Lancet 2009;373:811-820.
29. The writing committee on behalf of the ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. The Lancet 2009;373:125-136.
30. The START Trialists' Group.The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet 2009;371:1098-1107.
31. MMuers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. The Lancet 2008;371:1685-1694.
32. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. The Lancet 2007;370:143-152. (Pubitemid 47042894)
33. Guillou PJ, Quirke P, Thorpe H et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. The Lancet 2005;365:1718-1726. (Pubitemid 40719107)
34. Jayne DG, Guillou PJ, Thorpe H et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol 2007;25:3061-3068. (Pubitemid 47224732)
35. Dearnaley DP, Sydes MR, Graham JD et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. The Lancet Oncology 2007;8:475-487. (Pubitemid 46805903)
36. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. The Lancet 2007;370:2020-2029.
37. Mansel RE, Fallowfield L, Kissin M et al. Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial. JNCI J Natl Cancer Inst 2006;98:599-609. (Pubitemid 43904843)
38. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
39. Cunningham D, Allum WH, Stenning SP et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med 2006;355:11-20.
40. Cullen M, Steven N, Billingham L et al. Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas. N Engl J Med 2005;353:988-998. (Pubitemid 41262333)
41. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-12. (Pubitemid 36196730)